Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting.

about

Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting.

Item

http://www.wikidata.org/entity/Q46492914

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Multiple criteria decision ana ...... olders in the English setting.

@en

Multiple criteria decision ana ...... olders in the English setting.

@nl

type

Item

label

Multiple criteria decision ana ...... olders in the English setting.

@en

Multiple criteria decision ana ...... olders in the English setting.

@nl

prefLabel

Multiple criteria decision ana ...... olders in the English setting.

@en

Multiple criteria decision ana ...... olders in the English setting.

@nl

P1476

Multiple criteria decision ana ...... holders in the English setting

@en

P2093

Daniel Hochhauser

http://www.w3.org/2001/XMLSchema#string

Gilberto Montibeller

http://www.w3.org/2001/XMLSchema#string

Panos Kanavos

http://www.w3.org/2001/XMLSchema#string

P2860

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after fir

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

A review and classification of approaches for dealing with uncertainty in multi-criteria decision analysis for healthcare decisions

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

EGFR antagonists in cancer treatment

Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications.

Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.

P2888

s12911-017-0524-3

P304

149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12911-017-0524-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Aris Angelis

P577

2017-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092349631

http://www.w3.org/2001/XMLSchema#string

P698

29073892

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5658981

http://www.w3.org/2001/XMLSchema#string